TL;DR
- 1.TRIUMPH-1 Phase 3 results (May 2026): retatrutide 12 mg produced 28.3% average body weight loss in 2,339 people over 80 weeks. At 104 weeks, participants with BMI over 35 averaged 30.3% loss (roughly 85 lbs).
- 2.Retatrutide hits three receptors: GLP-1R (appetite reduction), GIPR (satiety and glucose control), and GCGR (the glucagon receptor). That third receptor boosts resting metabolic rate, which semaglutide and tirzepatide structurally cannot do.
- 3.45% of participants on the 12 mg dose lost 30% or more of body weight. In semaglutide trials, roughly 5% reach that threshold.
- 4.Not FDA approved as of June 2026. No NDA has been submitted. Compounding is explicitly prohibited by an FDA action from September 2025.
- 5.Your GLP-1, GIP, and glucagon receptor genes each influence a separate component of how retatrutide works. A GLP1R variant that blunts semaglutide response does not prevent the thermogenic benefit from the GCGR component.
Retatrutide delivered 28.3% average body weight loss in Phase 3 trials. The best-performing GLP-1 drug before it, tirzepatide, averaged 20.9% in its pivotal trial. That gap is not a rounding error. It is the difference between 55 lbs and 74 lbs for a 265-pound person. And it comes down to one thing: a third receptor that every approved drug before it ignored.
Eli Lilly announced TRIUMPH-1 results on May 21, 2026. In 2,339 participants over 80 weeks, the 12 mg dose produced 28.3% average weight loss. At 104 weeks, participants with BMI over 35 averaged 30.3%, roughly 85 lbs for the average participant in that subgroup. More than 45% of people on the 12 mg dose lost at least 30% of their starting body weight. In prior GLP-1 trials, fewer than 10% typically hit that threshold.
Average body weight lost at 104 weeks by TRIUMPH-1 participants with BMI over 35 on retatrutide 12 mg. That is approximately 85 lbs for the average participant in that subgroup. Source: Eli Lilly TRIUMPH-1 press release, May 2026.
This article covers what the TRIUMPH trial data actually shows, how the triple agonist mechanism produces more weight loss than existing drugs, and why your GLP-1, GIP, and glucagon receptor genes each change how much you respond. If you already understand how GLP-1 drugs work, our breakdown of why some people barely respond to semaglutide is the best place to start before reading this.
Think of obesity drugs as having two tools: turning down your appetite and turning up your metabolism. Ozempic uses one lever (appetite). Mounjaro uses two (appetite plus a satiety signal). Retatrutide uses all three, including a third lever that makes your body burn more calories at rest. That third lever is the glucagon receptor. Most people associate glucagon with raising blood sugar, which is accurate. But when you suppress the blood sugar effect through the other two receptors simultaneously, you can use glucagon's metabolic acceleration without the spike. That is the engineering difference that separates retatrutide from every drug that came before it.
Why Does Activating a Glucagon Receptor Cause More Weight Loss?
Glucagon is the hormone that tells your liver to release stored glucose when blood sugar drops. Everyone learns that glucagon does the opposite of insulin. So why would activating the glucagon receptor help with weight loss?
Because glucagon does more than raise blood sugar. In the liver, glucagon receptor activation also increases fat oxidation and raises resting energy expenditure. Research in the journal Diabetes showed that glucagon co-agonism alongside GLP-1 receptor activation produces greater fat mass reduction than either pathway alone, specifically because the liver shifts into a higher fat-burning state to supply the energy the glucagon signal demands.
The blood sugar problem gets neutralized by the GLP-1 receptor component. GLP-1R agonism increases insulin secretion and suppresses glucagon-driven hepatic glucose release. So you get the metabolic acceleration without the hyperglycemia, because the GLP-1 arm prevents that side effect in the same molecule.
"Retatrutide acts on three complementary pathways: GLP-1 receptor agonism reduces caloric intake, GIP receptor agonism enhances glucose disposal and satiety, and glucagon receptor agonism increases energy expenditure. The combination produces weight loss that exceeds any single or dual agonist by a clinically meaningful margin."
Eli Lilly investor presentation, TRIUMPH-1 Phase 3 data readout, May 2026
This is the part most retatrutide coverage misses. People assume it is a more powerful Ozempic. It is not. It uses a different mechanism for roughly 30 to 40% of its weight loss effect. The GCGR component is not amplifying what GLP-1 already does. It is adding a separate metabolic pathway that GLP-1 drugs structurally cannot reach.
GLP-1R, GIPR, and GCGR: What Each Receptor Actually Does
GLP-1R: The Appetite Lever
The receptor semaglutide targets exclusively. GLP-1R agonism slows gastric emptying, suppresses appetite through the hypothalamus and brainstem, and stimulates glucose-dependent insulin secretion. This is where roughly 40 to 50% of retatrutide's weight loss effect comes from. Your GLP1R gene variants predict how well this specific component works for you. A GLP1R variant that blunted your semaglutide results will blunt this component of retatrutide too, but not the other two.
GIPR: The Satiety Amplifier
The second receptor tirzepatide added to create a dual agonist. GIPR agonism potentiates the GLP-1 effect, improves glucose tolerance, and appears to reduce GI side effects compared to GLP-1 mono-therapy alone. Adding GIPR co-agonism pushed tirzepatide's average result roughly 5 to 6 percentage points above semaglutide. Retatrutide uses this receptor as its middle layer. The GIPR gene variant E354Q (present in about 30% of people of European descent) alters receptor sensitivity and appears in full coverage on our genetic panel.
GCGR: The Metabolic Accelerator
The receptor no approved obesity drug has used before retatrutide. GCGR agonism in the liver increases fat oxidation and raises resting metabolic rate. This is the thermogenic component. Unlike appetite suppression (which requires ongoing dosing to stay in effect), the resting metabolic rate increase from GCGR agonism operates in parallel with the caloric restriction the other two receptors drive. People with GCGR variants that reduce receptor expression will see a blunted thermogenic response specifically, even if their GLP-1 and GIP components work normally.
The result of stacking all three is that retatrutide produces both intake restriction AND energy expenditure increase simultaneously. No other approved obesity drug as of 2026 achieves both. For context on how different peptide structures affect receptor engagement, see our overview of how peptides reach their target receptors by route.
What the TRIUMPH Phase 3 Data Actually Shows
TRIUMPH-1 was the pivotal obesity trial: 2,339 participants, 80 weeks, three doses plus placebo. Eli Lilly announced results on May 21, 2026. A second Phase 3 trial (TRIUMPH-4, obesity plus knee osteoarthritis) completed in December 2025 with similar results at 68 weeks.
| Drug and Dose | Average weight loss | Users losing 20%+ | Users losing 30%+ | Trial weeks |
|---|---|---|---|---|
| Semaglutide 2.4 mg (STEP-1) | ~15.0% | ~32% | ~5% | 68 |
| Tirzepatide 15 mg (SURMOUNT-1) | ~20.9% | ~56% | ~18% | 72 |
| Retatrutide 4 mg (TRIUMPH-1) | 17.6% | ~38% | ~8% | 80 |
| Retatrutide 9 mg (TRIUMPH-1) | 23.7% | ~59% | ~28% | 80 |
| Retatrutide 12 mg (TRIUMPH-1) | 28.3% | ~73% | 45.3% | 80 |
| Placebo (TRIUMPH-1) | 3.9% | n/a | n/a | 80 |
The 30%+ responder rate is the most striking number in this table. In semaglutide STEP-1, roughly 5% of participants lost 30% or more of body weight at 68 weeks. In SURMOUNT-1 at the tirzepatide ceiling dose, about 18% hit that threshold. In TRIUMPH-1 at 12 mg retatrutide, 45.3% crossed it. At 104 weeks, the average for high-BMI participants was 30.3%. The drug did not appear to fully plateau at 80 weeks.
Share of TRIUMPH-1 participants on retatrutide 12 mg who lost 30% or more of body weight. In the semaglutide STEP-1 trial, roughly 5% reached that same threshold. Source: Eli Lilly TRIUMPH-1 data readout, May 2026.
TRIUMPH-4 (December 2025) tested retatrutide in people with obesity and knee osteoarthritis. The 12 mg dose produced 28.7% weight loss at 68 weeks in that population, confirming the TRIUMPH-1 efficacy signal was not a one-trial anomaly. The knee pain scores also improved substantially, which Eli Lilly is likely to use as a secondary label claim if the NDA clears.
How Does This Compare to Ozempic for Someone Who Already Tried It?
You cannot do a direct statistical comparison of TRIUMPH-1 to STEP-1 because the trials differed in duration, baseline BMI, and titration protocols. But you can follow the logic of who responds to what.
If you tried semaglutide and lost less than 5% of your body weight despite adherence, you are likely a GLP-1 partial non-responder. That means the GLP-1R component of retatrutide will also underperform for you. But the GIPR and GCGR components are entirely separate pathways with separate genetic predictors. A GLP1R variant does not prevent the metabolic rate increase from GCGR agonism. The net result is that some people who respond poorly to semaglutide may respond substantially better to retatrutide specifically because of the third receptor.
If you took tirzepatide (dual GLP-1 plus GIP) and hit a plateau, the GCGR component is the new variable. Tirzepatide cannot access that pathway. Retatrutide specifically adds the thermogenic uplift that tirzepatide was missing. This is why moving from tirzepatide to retatrutide is a mechanistically different question from moving from semaglutide to tirzepatide.
Our guide to weight loss peptides and genetics goes deeper on the specific SNPs that predict GLP-1 class response and how to interpret them alongside a GIP and GCGR panel.
Can You Get Retatrutide in 2026?
No, not through any legal channel available to the general public. As of June 2026, retatrutide has no FDA approval and Eli Lilly has not yet submitted an NDA. Based on the TRIUMPH-1 data released in May 2026 and the TRIUMPH-4 data from December 2025, an NDA submission is expected in late 2026 or early 2027. Under priority review, approval could come in late 2027. Under standard review, the realistic window is early to mid-2028.
In September 2025, the FDA explicitly prohibited compounding of retatrutide. Unlike semaglutide and tirzepatide (which entered a legal compounding gray zone during drug shortage periods), retatrutide cannot be compounded because it has never been approved, never appeared on a drug shortage list, and has no USP compendial monograph. Any vendor advertising compounded retatrutide as of 2026 is operating outside FDA enforcement parameters.
Clinical trial enrollment is the only route for access in mid-2026. Eli Lilly has multiple active TRIUMPH-program trials. If you want to track eligibility, search ClinicalTrials.gov for "retatrutide" to see currently enrolling sites and criteria.
Side Effects: The GI Burden of Adding a Third Receptor
Retatrutide's most common adverse events match the GLP-1 class: nausea, diarrhea, constipation, and vomiting. The Phase 3 reported nausea in approximately 33% of participants at the 12 mg dose. Constipation occurred in roughly 25%. Vomiting ranged from 10 to 25% depending on dose level and titration timing.
Discontinuation due to adverse events in TRIUMPH-1 was 4.1% at 4 mg, 6.9% at 9 mg, and 11.3% at 12 mg. For context, tirzepatide SURMOUNT-1 reported discontinuation of about 7 to 8% at the ceiling dose. Retatrutide's GI burden at the highest dose appears somewhat higher, which is the likely cost of adding the GCGR metabolic acceleration on top of dual GLP-1 plus GIP agonism.
The titration schedule is the most important tolerability variable. TRIUMPH-1 used a slow escalation starting at 1 mg and ramping over months to reach 12 mg. Participants who followed the titration schedule tolerated the drug significantly better than those who escalated faster. The approved label, if the NDA clears, will almost certainly codify a slow-ramp requirement.
Does Your DNA Predict How Well Retatrutide Will Work for You?
Yes, through three separate pathways, one per receptor target. This matters more for retatrutide than for any previous weight loss drug because the three components have independent genetic predictors.
The GLP1R gene carries variants that predict appetite-reduction response. The best-studied is an Ala316Thr substitution where carriers show reduced GLP-1 receptor activity. In a 27,000-person semaglutide registry, carriers lost about 4 percentage points less on average. That same GLP1R architecture underlies the GLP-1R component of retatrutide, meaning your semaglutide response history is a reasonable proxy for how that specific piece of retatrutide will perform for you specifically.
The GIPR gene carries a common variant (E354Q, present in roughly 30% of people of European descent) that alters GIP receptor sensitivity. Whether this variant improves or worsens GIP-pathway response to a drug like retatrutide remains actively debated in the literature as of 2026. But it is genetically distinct from GLP1R variants and does not predict the same outcomes.
The GCGR gene is the most undercovered of the three in published pharmacogenomics literature, because no approved drug has targeted it before. GCGR variants affect baseline glucagon receptor density and downstream signaling efficiency in the liver. Your GCGR profile determines how much thermogenic uplift you get from the third agonist component, and it is entirely possible that the responder vs non-responder gap in TRIUMPH-1's highest-dose group comes partly from GCGR variation that the trial was not designed to measure.
Our retatrutide peptide page covers all three receptor gene panels and their interaction. If you have already uploaded your genetic data, the report already includes a GLP1R and GIPR coverage estimate. Once Eli Lilly files the NDA and GCGR-specific pharmacogenomic data from TRIUMPH becomes available, we will update the prediction model accordingly.
Verdict: The most effective obesity drug ever tested in humans, and not currently available to the public. Retatrutide's 28.3% average weight loss and 45% rate of achieving 30%-plus loss represent a category shift. The triple receptor mechanism, particularly the GCGR thermogenic component, does something semaglutide and tirzepatide cannot do by design. If you are a semaglutide non-responder, the GIPR and GCGR components work through pathways entirely independent of your GLP-1 receptor status. FDA approval is realistically late 2027 to early 2028. The question worth answering now is whether your genetic profile places you in the category that responds at 30% or the one that responds at 15%. Upload your genetic data or order a kit to find out before enrollment options open.
Your DNA shapes how you respond to the peptides discussed above.
A personalized report scores 25+ peptides against your unique genetic profile — including the ones covered in this article.
Frequently asked questions
How much weight can you lose on retatrutide?
In the TRIUMPH-1 Phase 3 trial (results announced May 2026), participants on retatrutide 12 mg lost an average of 28.3% of body weight over 80 weeks. At 104 weeks, participants with BMI over 35 averaged 30.3%, roughly 85 lbs. More than 45% of the highest-dose group lost 30% or more of starting body weight, a result not seen with any previously approved drug.
Is retatrutide approved by the FDA?
No. As of June 2026, retatrutide is not FDA approved and Eli Lilly has not yet submitted an NDA. Phase 3 data from TRIUMPH-1 was announced in May 2026. An NDA submission is expected in late 2026 or early 2027, with potential FDA approval in late 2027 under priority review or early to mid-2028 under standard review.
What makes retatrutide different from tirzepatide (Mounjaro or Zepbound)?
Tirzepatide is a dual agonist targeting GLP-1 and GIP receptors. Retatrutide adds a third receptor: the glucagon receptor (GCGR). Activating GCGR increases resting energy expenditure and fat oxidation in the liver, a thermogenic effect that tirzepatide cannot produce. This third mechanism is responsible for the additional 7 to 8 percentage points of average weight loss retatrutide shows above tirzepatide in trial data.
What are the side effects of retatrutide?
The most common side effects in TRIUMPH-1 were nausea (roughly 33% at 12 mg), constipation (roughly 25%), diarrhea, and vomiting. Discontinuation due to adverse events was 11.3% at the highest dose, compared to 7 to 8% for tirzepatide at its ceiling dose. GI side effects are dose-dependent and largely manageable with slow titration.
Can you get retatrutide through a compounding pharmacy?
No. In September 2025, the FDA explicitly prohibited compounding of retatrutide because it is an unapproved drug with no shortage history, no USP monograph, and no approved reference product. This prohibition applies nationally. Clinical trial enrollment is the only legal route to retatrutide as of mid-2026.
What genes predict how well retatrutide will work?
Three separate gene systems are relevant: GLP1R (predicts appetite-suppression response), GIPR (predicts satiety-amplification response), and GCGR (predicts thermogenic and metabolic-rate response). These are independent predictors. A GLP1R variant that blunted your semaglutide response does not blunt the GCGR component, which is why some semaglutide non-responders may see substantially better results with retatrutide.
How does the Phase 3 retatrutide data compare to the Phase 2 results?
Phase 2 (published in the New England Journal of Medicine in 2023) showed 24.2% weight loss at the highest dose over 48 weeks. Phase 3 TRIUMPH-1 improved on that result at 28.3% over 80 weeks, which reflects both the longer duration and the optimized titration schedule used in the larger trial. The Phase 3 data also confirmed continued weight loss past week 80 in extended sub-analyses.
This article is for informational and educational purposes only. It is not medical advice and does not diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare professional before starting any peptide protocol. Individual results vary.